Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

F. Hoffmann-La Roche Ag

Humberto Bartolome Arzeno

Eric Roy Humphreys

Christopher R Roberts

Paul Ross Fatheree

David Michael Goldstein

Colin C Beard

Lawrence Emerson Fisher

Charles Alois Dvorak

Douglas L Wren

Yeun-Kwei Han

Sam Linh Nguyen

Jan P Lund

Steven D Axt

James Patrick Dunn

Jian Jeffrey Chen

Leyi Gong

Wylie Solang Palmer

Tania M Silva

Julie Anne Lim

Jim-wah Wong

David John Morgans, Jr

Jiang Zhu

Alam Jahangir

Keshab Sarma

John J Nestor, Jr

David Mark Rotstein

Shao-Yong Wu

Gary M Lee

Joan Heather Hogg

Bradley E Loe

Xiaochun Han

Teresa Alejandra Trejo-Martin

Michael Martin

Deborah Carol Reuter

Yun-chou Tan

Parcharee Tivitmahaisoon

Lubov Konstantinovna Filonova

Yun-Chou Tan

Erin M O'Brien

Natalie L McClure

Lubov Filonova

Tania Silva

Inhibitors of JNK

The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R, R, R, X, X, X, X, X, X, Y, Y, Zand Zare as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

The present process provides a improved method for the preparation of alkylsulfanyl substituted triazoles 2 which are useful intermediates in a new process for the preparation of triazolones 20. 

Process for preparing triazolones

A fragment condensation process for the synthesis of analogs of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP), in which amino acid residues (22-31) form a synthetic amphipathic &#x3b1;-helix, is provided.

Method for the synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide

7-oxo-pyridopyrimidines (II)

Process for preparing a 2-(2-amino-1, 6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative

Process for preparing intermediates of formula (III)

Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative

Intermediates of Formula (III) ##STR1## wherein P.sup.1 is hydrogen or an amino-protecting group, R is lower alkyl, allyl or aralkyl, and Z is hydrogen, lower alkyl, aryl or aralkyl; and Formula (VI) ##STR2## wherein P.sup.1 is hydrogen or an amino-protecting group, P.sup.2 is an amino protecting group, and Z is hydrogen, lower alkyl, aryl or aralkyl, are useful in a novel process for preparing the mono-L-valine ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol (ganciclovir). The mono-L-valine ester of ganciclovir and its pharmaceutically acceptable salts are of value as antiviral agents with improved absorption.

Process for preparing a

Process and novel intermediates for preparing the L-mono-valine ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process and intermediates provide for reduced impurities in the mono-valine ester end-product and lower overall production costs. The process involves the condensation of a silylated guanine compound with a substituted glycerol derivative and esterification of this product with an L-valine derivative. These mono-valine products are of value as antiviral agents with improved absorption.

Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)

An .omega.-guanidino-.alpha.-amino-acid (or its functional derivative) or a compound containing it may be prepared by the reaction of the .omega.-amino group of an .alpha.,.omega.-diamino acid (or its functional derivative) or a compound containing it with a formamidinesulfonic acid.

Selective amidination of diamines

Process and novel intermediates for preparing the mono-L-valine ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol ganciclovir) and its pharmaceutically acceptable salts. The present process and monoester intermediates provide for mono-esterification by an L-valine derivative, resulting in a monocarboxylate-monovalinate which is then selectively hydrolyzed under basic or enzymatic conditions to give the monovaline ester of ganciclovir in high yield and purity. These products are of value as antiviral agents with improved absorption.

Process for preparing the L-monovaline ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process provides an N,O-bis-trityl intermediate of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol which allows for mono-esterification by an L-valine derivative. These products are of value as antiviral agents with improved absorption.

Process for preparing the L-monovaline ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process relates to an improved process whereby ganciclovir is esterified with an L-valine derivative to provide a di-valine ganciclovir intermediate. Removal of one of the valine groups with a lower alkyl amine, benzylamine or benzyl methylamine provides the mono-valine ester compound of Formula I. These products are of value as antiviral agents with improved absorption.

Growing community of inventors

Cupertino, CA, United States of America

Humberto Bartolome Arzeno